LOGIN  |  REGISTER
Terns Pharmaceuticals
Assertio

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

May 11, 2023 | Last Trade: US$0.97 0.11 12.56

CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets.

Palatin Technologies, Inc.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

  

Q3 Fiscal Year 2023 Results Press Release                                     

05/16/2023 at 7:30 a.m. ET

  

Q3 Fiscal Year 2023 Conference Call-Live                                     

05/16/2023 at 11:00 a.m. ET

     US Toll Free Dial-In Number:                                                     

1-888-506-0062

     International Dial-In Number:                                                     

1-973-528-0011

     Participant Access Code:                                                             

555988

  

Q3 Fiscal Year 2023 Conference Call-Replay                                 

05/16/2023-05/30/2023

     US Toll Free Dial-In Number:                                                     

1-877-481-4010

     International Dial-In Number:                                                     

1-919-882-2331

     Participant Access Code:                                                             

48459

  

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by accessing this link.

About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB